Business
Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity
Advancing IKT-001 into a Late-Stage Clinical Trial Program in Pulmonary Arterial HypertensionBOSTON and ATLANTA, May 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor therapeutics to treat pulmonary arterial hypertension (“PAH”), today reported financial results for the quarter ended March 31, 2025 and highlighted recent developments. “During our first quarter of
About this update from Inhibikase Therapeutics, Inc.
[{"type":"image","alt":"Inhibikase Therapeutics","displaySize":"","headline":null,"caption":"Inhibikase Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":136,"url":"https://media.zenfs.com/en/globenewswire.com/130e53897dc7f576187ef1917e07dc52"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Jrx7oJ.q30fX7LRFGfs16Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/130e53897dc7f576187ef1917e07dc52","width":300,"height":136}},"lazy":false},{"type":"text","content":"Advancing IKT-001 into a Late-Stage Clinical Trial Program in Pulmonary Arterial Hypertension","length":93,"tagName":"p"},{"type":"text","content":"BOSTON and ATLANTA, May 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor therapeutics to treat pulmonary arterial hypertension (“PAH”), today reported financial results for the quarter ended March 31, 2025 and highlighted recent developments.","length":378,"tagName":"p"},{"type":"text","content":"“During our first quarter of 2025, we continued to build out our senior leadership team and key infrastructure areas to position the Company to advance IKT-001 toward a late-stage clinical trial in PAH,” said Mark Iwicki, Chief Executive Officer of Inhibikase. “With our core team now in place, and with ongoing refining of our study protocol with key opinion leaders, IKT is well placed to initiate our Phase 2b clinical study of IKT-001 in PAH in the second half of 2025.” The IMPRES Phase 3 study of imatinib mesylate previously demonstrated improved exercise capacity and hemodynamics in patients with advanced PAH. We continue to believe that systemic exposure of imatinib with IKT-001 can be well tolerated and provide strong efficacy to patients suffering from PAH.","length":777,"tagName":"p"},{"type":"text","content":"Recent Developments:","length":20,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Announced the appointments of Mark Iwicki as Chief Executive Officer, Chris Cabell, M.D., M.H.S, FACC, as President and Head of Research & Development, and John Adams, Ph.D., as Chief Scientific Officer, and David McIntyre as Chief Financial Officer.","length":254,"tagName":"p"}]},{"val":[{"type":"text","...